CN102934790A - Blood pressure-reducing low sodium salt added with potassium chloride and chitosan oligosaccharide and production method of blood pressure-reducing low sodium salt - Google Patents
Blood pressure-reducing low sodium salt added with potassium chloride and chitosan oligosaccharide and production method of blood pressure-reducing low sodium salt Download PDFInfo
- Publication number
- CN102934790A CN102934790A CN2012105211955A CN201210521195A CN102934790A CN 102934790 A CN102934790 A CN 102934790A CN 2012105211955 A CN2012105211955 A CN 2012105211955A CN 201210521195 A CN201210521195 A CN 201210521195A CN 102934790 A CN102934790 A CN 102934790A
- Authority
- CN
- China
- Prior art keywords
- salt
- chitosan oligosaccharide
- blood pressure
- potassium chloride
- sodium salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a blood pressure-reducing low sodium salt added with potassium chloride and chitosan oligosaccharide and a production method of the blood pressure-reducing low sodium salt. The blood pressure-reducing low sodium salt comprises the following components in percent by weight of 60-83 percent of edible salt, 13-30 percent of potassium chloride, 3-9 percent of chitosan oligosaccharide and 0.1-1.0 percent of silica. The blood pressure-reducing low sodium salt provided by the invention has the advantages that the chitosan oligosaccharide is fused in the edible salt, so that people can take in a proper amount of chitosan oligosaccharide, the blood pressure reducing effect is far higher than that of the low sodium salt on the market; the immune modulating function of a human body can be effectively enhanced, hypertension, hyperlipidemia and hyperglycemia are reduced; according to the condition that the crowd in China is lack of potassium, the adding quantity of the potassium chloride is properly reduced, and the cost is saved under the condition of meeting the demand of replenishing the potassium in the human body; by utilizing a proper quantity of powdery refined salt and silica and other products, the quality problems of layering and blocking and the like are effectively avoided; and raw materials and auxiliary materials all belong to the food grade and are safe without side effects.
Description
Technical field
The present invention relates to a kind of Cardia Salt, particularly a kind of hypotensive Cardia Salt and production method thereof of adding potassium chloride, chitosan oligosaccharide.
Background technology
Salt is indispensable flavouring in people's daily life meals, but is proportionate and has become at present common recognition both domestic and external between the intake of salt and hypertension, cardiovascular disease, and edible salt intake is more, and blood pressure level is higher.World Health Organization recommends the edible salt intake of each per day for adults should be lower than 6g, and intake every day of the average salt of China resident be 12g, far above recommended amounts.China has become one of the most critical country of hypertension in the world.Current most scholar thinks that hypertension is relevant with the sodium ion in salt, therefore, world many countries has Cardia Salt, mainly with potassium chloride, magnesium sulfate Substitute For Partial sodium chloride, by improving the poised state of sodium in body, potassium, magnesium ion, reach prevention and control hypertensive purpose.Facts have proved, Cardia Salt is good selection to hyperpietic and old man.
Simultaneously, separately there are some medical researches to show that in salt, chlorion is also hypertension one of the most influential factor.Chlorion has activation to a kind of biology enzyme of angiotensins that cries on vascular wall, and angiotensin I converts Angiotensin II under the effect of angiotensins, causes hypertension.Current Cardia Salt is on the market compared with common salt, and the content of chlorion does not have to change substantially, and due to compatriots' eating habit, too high edible salt intake can cause that in human body, chlorine ion concentration is too high equally, thereby causes hypertension.
At occurring in nature, the chlorion that chitosan oligosaccharide can rely on exclusive positive charge in its structure to present negative electrical charge in body is combined, and excrete, simultaneously can the activating vessels cell, improve microcirculation, reduce peripheral vascular resistance, reduce serum cholesterol, alleviate artery sclerosis, thereby realize regulating the effect of blood pressure.
The chitosan oligosaccharide formal name used at school is β-Isosorbide-5-Nitrae-oligosaccharides-gucosamine, be the later widow of degradation of chitosan right be the low molecular weight product of 2-10.Shitosan is that the chitin extensively existed by nature obtains after deacetylated processing, is the unique abundant positively charged alkaline glycosaminoglycan that occurring in nature exists, and is a kind of cationic natural polymer animal food fiber of being with.Chitosan oligosaccharide, except inheriting all functional characteristics of shitosan, is compared with shitosan, and it is water-soluble better, more easily is absorbed by the body, and biologically active is stronger.Chitosan oligosaccharide participates in human body metabolism, has good biocompatibility, security and well-formedness.Except can be hypotensive, also there is the inhibition cancer cell growth, strengthen body immunity, promote calcium and mineral absorption, propagation lactic acid bacteria, Bifidobacterium etc., the functions such as reducing blood lipid, blood sugar, adjusting cholesterol; Can prevent and treat cardiovascular and cerebrovascular diseases, coronary heart disease, diabetes, apoplexy, canceration, stomach trouble etc.Chitosan oligosaccharide is called as the 6th vital principle, and scientist points out that people should absorb chitosan oligosaccharide as picked-up fat, protein, sugar, mineral matter, vitamin.
At present, on market, mainly chitosan oligosaccharide is applied in health products as a kind of functional food, usually makes capsule, preparation etc., popularity rate is not high.
Summary of the invention
The purpose of this invention is to provide a kind of hypotensive Cardia Salt, by add potassium chloride and chitosan oligosaccharide in edible salt, improve the concentration of potassium ion when reducing the interior sodium ion of human body and chlorine ion concentration, thereby reach prevention and control hypertensive purpose.
Technical scheme of the present invention is achieved in that
A kind of hypotensive Cardia Salt, the percentage by weight of its component is: edible salt 60～83%, potassium chloride 13～30%, chitosan oligosaccharide 3～9%, silica 0.3～1.0%.Preferably, each weight percentages of components is: edible salt 65 ~ 80%, potassium chloride 15 ~ 28%, chitosan oligosaccharide 4 ~ 8%, silica 0.5 ~ 0.8%.More preferably each weight percentages of components is: edible salt 70 ~ 74%, potassium chloride 20 ~ 25%, chitosan oligosaccharide 5 ~ 7%, silica 0.6 ~ 0.7%.
Wherein, chitosan oligosaccharide content lower than 3% the time, does not have the antihypertensive effect obtained, and chitosan oligosaccharide content is higher than 9% the time, and not obtaining obvious step-down improves effect, and originally sees it is not preferred from becoming.In addition, KCE content, lower than 13% or higher than 30% the time, does not have the antihypertensive effect obtained.
In a preferred embodiment, above-mentioned edible salt is divided into two parts, and the one, particle mean size is less than the powdery of 0.15mm (preferably being less than 0.1mm), and the 2nd, the thin crystalline form that particle mean size is 0.15mm～0.50mm (preferably 0.20mm～0.40mm).
Described powdery edible salt, the quality index except granularity meets purified salt seconds requirement in GB5461-2000 " edible salt ".Its addition accounts for 20～50wt% of edible salt amount.
Thin crystalline form edible salt raw material used, its moisture is controlled at 1.0～4.0wt%, and other batch of reference symbol closed purified salt seconds requirement in GB54612000 " edible salt ".Its addition accounts for 50～80wt% of edible salt amount.
Wherein, the purity of chitosan oligosaccharide is preferably more than 85% or more than 90wt%, can use the chitosan oligosaccharide of commercially available food stage.Preferably, chitosan oligosaccharide has and is less than 0.1mm, is more preferably less than 0.05mm, further preferably is less than the particle mean size of 0.01mm.The chitosan oligosaccharide of above-mentioned addition and granularity is added to the outward appearance of the hypotensive Cardia Salt of not obvious impact in salt.
The preparation method of above-mentioned hypotensive Cardia Salt is characterized in that: at first, powdery edible salt, silica are put into to mixer with chitosan oligosaccharide and mixed; Secondly, thin crystalline form edible salt is added in mixer and is mixed evenly; Finally potassium chloride is added in mixer and is mixed evenly, pack to obtain product.
Beneficial effect:
1. for the first time chitosan oligosaccharide is fused in edible salt, makes people can absorb appropriate chitosan oligosaccharide every day, blood pressure lowering effect is far away higher than Cardia Salt on the market;
2. product can effectively strengthen the human immunity regulatory function, reduces by three height;
3. according to current domestic crowd's potassium deficiency situation, product has suitably reduced the potassium chloride addition, is meeting under replenishing potassium conditions of demand, saves cost;
4. the application in product such as suitable powdery purified salt and silica, effectively avoid the quality problem such as product layering and caking;
5. the product supplementary material is all food stage, safely, have no side effect.
The specific embodiment
By the following examples, the present invention will be further described.Example, only for explaining the present invention, is not intended to limit scope of the present invention.
Embodiment 1
Described edible salt is purified salt, and potassium chloride and chitosan oligosaccharide are all food stage, and silica is food additive grade.Chitosan oligosaccharide is faint yellow or the white powder commercially available prod, and purity is more than 85% or more than 90%.
By powdery edible salt 165kg, silica 5kg, put into mixer with chitosan oligosaccharide 30kg and mix; Secondly, thin crystalline form edible salt 660kg is added in mixer and is mixed evenly; Finally potassium chloride 140kg is added in mixer and is mixed evenly, pack to obtain hypotensive Cardia Salt.
Embodiment 2
Described edible salt is purified salt, and potassium chloride and chitosan oligosaccharide are all food stage, and silica is food additive grade.Chitosan oligosaccharide is the pale yellow powder commercially available prod, and purity is more than 85%.
By powdery edible salt 152kg, silica 1 0kg, put into mixer with chitosan oligosaccharide 30kg and mix; Secondly, thin crystalline form edible salt 608kg is added in mixer and is mixed evenly; Finally potassium chloride 200kg is added in mixer and is mixed evenly, pack to obtain hypotensive Cardia Salt.
Embodiment 3
Described edible salt is purified salt, and potassium chloride and chitosan oligosaccharide are all food stage, and silica is food additive grade.Chitosan oligosaccharide is the pale yellow powder commercially available prod, and purity is more than 85%.
By powdery edible salt 240kg, silica 1 0kg, put into mixer with chitosan oligosaccharide 60kg and mix; Secondly, thin crystalline form edible salt 490kg is added in mixer and is mixed evenly; Finally potassium chloride 200kg is added in mixer and is mixed evenly, pack to obtain hypotensive Cardia Salt.
Embodiment 4
Described edible salt is purified salt, and potassium chloride and chitosan oligosaccharide are all food stage, and silica is food additive grade.Chitosan oligosaccharide is the pale yellow powder commercially available prod, and purity is more than 85%.
By powdery edible salt 300kg, silica 1 0kg, put into mixer with chitosan oligosaccharide 90kg and mix; Secondly, thin crystalline form edible salt 300kg is added in mixer and is mixed evenly; Finally potassium chloride 300kg is added in mixer and is mixed evenly, pack to obtain hypotensive Cardia Salt.
Comparative example 1
Described edible salt is purified salt, and potassium chloride and chitosan oligosaccharide are all food stage, and silica is food additive grade.Chitosan oligosaccharide is pale yellow powder, and purity is more than 85%.
By powdery edible salt 275kg, silica 1 0kg, put into mixer with chitosan oligosaccharide 25kg and mix; Secondly, thin crystalline form edible salt 490kg is added in mixer and is mixed evenly; Finally potassium chloride 200kg is added in mixer and is mixed evenly, pack to obtain the hypotensive Cardia Salt of comparative example 1.
Comparative example 2
Described edible salt is purified salt, and potassium chloride is all food stage, and silica is food additive grade.Chitosan oligosaccharide is pale yellow powder, and purity is more than 85%.
Powdery edible salt 300kg is put into to mixer with silica 1 0kg to be mixed; Secondly, thin crystalline form edible salt 490kg is added in mixer and is mixed evenly; Finally potassium chloride 200kg is added in mixer and is mixed evenly, pack to obtain the hypotensive Cardia Salt of comparative example 2.
Antihypertensive effect is estimated
Verify the antihypertensive effect of this product by random short-term check experiment.Select 60 ages between 40 one full year of life one full year of life to 65, the primary hypertension patient of systolic pressure >=160mmHg is as research object, gets rid of the object of infringement histories such as defining the obvious heart, liver, kidney.All research objects adopt randomize routine to be divided at random three groups by computer, every group 20, within continuous 10 days, under standard conditions, by unified standard, use electronic sphygmomanometer Measure blood pressure value (comprising systolic pressure and diastolic pressure), get respectively mean value systolic pressure and the diastolic pressure front as test of contractive pressure and diastolic pressure.Then, the food of the Cardia Salt cooking of first group of edible use every day embodiment of the present invention 3, the food of the Cardia Salt cooking of second group of edible use every day comparative example 1, the food of the Cardia Salt cooking of the 3rd group of edible use every day comparative example 2, the edible salt intake of controlling for each person every day is 6g, edible 6 months continuously.Measured a research object pressure value every 10 days after starting to eat 1 month, until full 6 months, then by systolic pressure and diastolic blood pressure values after each the average rear acquisition test of measured value.Systolic pressure/diastolic pressure before and after comparative test, return normal value or systolic pressure with the systolic pressure/diastolic pressure (systolic pressure surpasses 140mmHg or diastolic pressure surpasses 90mmHg) that exceeds normal value and reduce at least the above and blood pressure of 20mmHg and keep comparatively steadily being expressed as effectively.Wherein, at duration of test, the former medication treatment of patient, by former same dosage and mode, take medicine.As a result, in using the group of embodiment 3, the systolic pressure 26.05mmHg that on average descends, the diastolic pressure 15.29mmHg that on average descends, 15 patients are effective; In using the group of comparative example 1, the systolic pressure 22.61mmHg that on average descends, the diastolic pressure 11.58mmHg that on average descends, 7 patients are effective; And in using the group of comparative example 2, the systolic pressure 15.20mmHg that on average descends, the diastolic pressure 8.73mmHg that on average descends, only have 2 patients effective.
Claims (7)
1. a hypotensive Cardia Salt that adds potassium chloride, chitosan oligosaccharide, is characterized in that: mean by weight percentage edible salt 60～83%, potassium chloride 13～30%, chitosan oligosaccharide 3～9%, silica 0.3～1.0%.
2. hypotensive Cardia Salt according to claim 1, is characterized in that: mean by weight percentage edible salt 65 ~ 80%, potassium chloride 15 ~ 28%, chitosan oligosaccharide 4 ~ 8%, silica 0.5 ~ 0.8%.
3. hypotensive Cardia Salt according to claim 2, is characterized in that: edible salt 70 ~ 74%, potassium chloride 20 ~ 25%, chitosan oligosaccharide 5 ~ 7%, silica 0.6 ~ 0.7%.
4. according to the described hypotensive Cardia Salt of any one in claim 1 ~ 3, it is characterized in that: above-mentioned edible salt is divided into two parts, and the one, particle mean size is less than the powdery of 0.15mm, and the 2nd, the thin crystalline form that particle mean size is 0.15mm～0.50mm.
5. hypotensive Cardia Salt according to claim 4 is characterized in that: the addition that described granularity is less than 0.15mm powdery edible salt accounts for 20～50 % by weight of edible salt amount; Described granularity is the thin crystalline form edible salt of 0.15mm～0.50mm raw material, and its moisture is controlled at 1.0～4.0%, and its addition accounts for 50～80 % by weight of edible salt amount.
6. according to the described hypotensive Cardia Salt of any one in claim 1 ~ 5, it is characterized in that: the purity of chitosan oligosaccharide is more than 85%.
7. the preparation method of the hypotensive Cardia Salt of any one in claim 1 ~ 6, is characterized in that: at first, powdery edible salt, silica are put into to mixer with chitosan oligosaccharide and mixed; Secondly, thin crystalline form edible salt is added in mixer and is mixed evenly; Finally potassium chloride is added in mixer and is mixed evenly, pack to obtain product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105211955A CN102934790A (en) | 2012-12-07 | 2012-12-07 | Blood pressure-reducing low sodium salt added with potassium chloride and chitosan oligosaccharide and production method of blood pressure-reducing low sodium salt |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105211955A CN102934790A (en) | 2012-12-07 | 2012-12-07 | Blood pressure-reducing low sodium salt added with potassium chloride and chitosan oligosaccharide and production method of blood pressure-reducing low sodium salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102934790A true CN102934790A (en) | 2013-02-20 |
Family
ID=47693749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012105211955A Pending CN102934790A (en) | 2012-12-07 | 2012-12-07 | Blood pressure-reducing low sodium salt added with potassium chloride and chitosan oligosaccharide and production method of blood pressure-reducing low sodium salt |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102934790A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103271325A (en) * | 2013-05-15 | 2013-09-04 | 宋杰 | Edible salt with healthcare function |
| CN104222999A (en) * | 2014-09-26 | 2014-12-24 | 大连雅威特生物技术股份有限公司 | Composition, preparation and application of a novel low-sodium salt |
| CN105919018A (en) * | 2016-04-22 | 2016-09-07 | 吴彪 | Chitosan oligosaccharide solid composite seasoning and preparation method thereof |
| CN105919019A (en) * | 2016-04-28 | 2016-09-07 | 王寅 | Chitosan oligosaccharide salt and preparation method thereof |
| CN106072409A (en) * | 2016-07-06 | 2016-11-09 | 中盐国本盐业有限公司 | Functional flavoring agent of prebiotics and preparation method thereof |
| CN108719932A (en) * | 2017-04-24 | 2018-11-02 | 罗成 | A kind of functionality edible salt/Cardia Salt and its application |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1387794A (en) * | 2002-07-08 | 2003-01-01 | 岳静 | Health table salt |
| KR20030087468A (en) * | 2002-05-10 | 2003-11-14 | 정만종 | Manufacturing method of health salt included chito oligosaccharides and the salt by the method |
| KR20040102921A (en) * | 2003-05-30 | 2004-12-08 | 배조정 | A manufacture method of functional salt |
| KR100528963B1 (en) * | 2003-12-02 | 2005-11-15 | 바이오코트(주) | The composition and preparation of functional chitosan oligomers salts including opuntia ficus indaica or green tea powder |
| US20080085360A1 (en) * | 2006-10-05 | 2008-04-10 | Sambasiva Rao Chigurupati | Method for Producing a Low Sodium Salt Composition |
| EP1631155B1 (en) * | 2003-05-19 | 2008-09-24 | Cho, Gun Sik | Method for producing a chitosan containing salt having a function of lowering blood pressure |
| CN102266038A (en) * | 2011-08-24 | 2011-12-07 | 刘红玲 | Low sodium mineral salt and preparation method thereof |
-
2012
- 2012-12-07 CN CN2012105211955A patent/CN102934790A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030087468A (en) * | 2002-05-10 | 2003-11-14 | 정만종 | Manufacturing method of health salt included chito oligosaccharides and the salt by the method |
| CN1387794A (en) * | 2002-07-08 | 2003-01-01 | 岳静 | Health table salt |
| EP1631155B1 (en) * | 2003-05-19 | 2008-09-24 | Cho, Gun Sik | Method for producing a chitosan containing salt having a function of lowering blood pressure |
| KR20040102921A (en) * | 2003-05-30 | 2004-12-08 | 배조정 | A manufacture method of functional salt |
| KR100528963B1 (en) * | 2003-12-02 | 2005-11-15 | 바이오코트(주) | The composition and preparation of functional chitosan oligomers salts including opuntia ficus indaica or green tea powder |
| US20080085360A1 (en) * | 2006-10-05 | 2008-04-10 | Sambasiva Rao Chigurupati | Method for Producing a Low Sodium Salt Composition |
| CN102266038A (en) * | 2011-08-24 | 2011-12-07 | 刘红玲 | Low sodium mineral salt and preparation method thereof |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103271325A (en) * | 2013-05-15 | 2013-09-04 | 宋杰 | Edible salt with healthcare function |
| CN104222999A (en) * | 2014-09-26 | 2014-12-24 | 大连雅威特生物技术股份有限公司 | Composition, preparation and application of a novel low-sodium salt |
| CN105919018A (en) * | 2016-04-22 | 2016-09-07 | 吴彪 | Chitosan oligosaccharide solid composite seasoning and preparation method thereof |
| CN105919019A (en) * | 2016-04-28 | 2016-09-07 | 王寅 | Chitosan oligosaccharide salt and preparation method thereof |
| CN106072409A (en) * | 2016-07-06 | 2016-11-09 | 中盐国本盐业有限公司 | Functional flavoring agent of prebiotics and preparation method thereof |
| CN108719932A (en) * | 2017-04-24 | 2018-11-02 | 罗成 | A kind of functionality edible salt/Cardia Salt and its application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102934790A (en) | Blood pressure-reducing low sodium salt added with potassium chloride and chitosan oligosaccharide and production method of blood pressure-reducing low sodium salt | |
| CN101642152A (en) | Assistant hypoglycemic healthcare biscuits | |
| CN103211150B (en) | Polypeptide food containing active earthworm protein | |
| CN102783636A (en) | Food nutrition supplement for prophylaxis and treatment of diabetes and application thereof | |
| KR100421466B1 (en) | Manufacturing Method of Absorptive Zinc-Oligopeptide in The Human Body | |
| CN102113652A (en) | Special dietary extruded rice applicable to patients suffering from 'five-high' metabolic syndrome and preparation method thereof | |
| CN103125808A (en) | Antioxidant composite tablet for beauty and preparation method thereof | |
| CN105285127A (en) | Isomalto-oligosaccharide, fructo-oligosaccharide, and polydextrose containing healthcare milk powder for middle aged and old people | |
| CN102018158A (en) | Aloe jam | |
| CN103202456A (en) | Blood pressure reducing food salt and production method | |
| CN105433344A (en) | Selenium-rich table salt | |
| CN101341915A (en) | Multifunctional health tea | |
| CN101224005B (en) | Nutrient tablet possessing whole nutrient supplementing efficacy and producing method thereof | |
| CN1718117A (en) | Instant drinking powder contg. black-fungus, oatmeal and spirulina, and its prepn. method | |
| CN102178159A (en) | Carrot noodles | |
| CN105248944A (en) | Production method of potassium-rich and carotene-rich eggs | |
| CN101642476A (en) | Production method of organic selenium ganoderma lucidum spore powder | |
| CN101601470A (en) | Lucid ganoderma grain vinegar | |
| KR100734944B1 (en) | Functional health food composition based on calcium lactate and rice bran | |
| CN105647774A (en) | Sugar apple fruit vinegar and manufacturing method thereof | |
| CN103156120A (en) | Gynostemma pentaphyllum nutritional diet porridge | |
| CN106912929A (en) | A kind of health food nutritional agents and preparation method with anti-fatigue effect | |
| CN105248945A (en) | Production method of potassium-enriched and calcium-enriched eggs | |
| JP3159726U (en) | Substitute bread | |
| CN110447894A (en) | Natural mineral supplement capable of effectively preventing and improving cardiovascular and cerebrovascular diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130220 |